Back to Search
Start Over
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
- Source :
-
Circulation . 10/23/2018, Vol. 138 Issue 17, p1904-1907. 4p. - Publication Year :
- 2018
-
Abstract
- The article presents a study which examines cardiovascular outcome with empagliflozin in patients with type 2 diabetes mellitus (T2DM). Empagliflozin Cardiovascular Outcome Event Trial in T2DM Patients and analysis of the risk of cardiovascular disease were conducted in the study which involved 7020 patient with T2DM and cardiovascular disease (CVD). Results highlight the benefit of empagliflozin on the risks of cardiovascular death but demonstrate minor impact of glycemic control.
Details
- Language :
- English
- ISSN :
- 00097322
- Volume :
- 138
- Issue :
- 17
- Database :
- Academic Search Index
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 132530843
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.118.035759